The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
Abstract
BACKGROUND: In patients with acute myocardial infarction (MI), therapies that could further reduce the risk of adverse cardiovascular and metabolic outcomes are needed. METHODS: In this international registry-based, randomized, double-blind trial, patients without prior diabetes or chronic heart failure, presenting with acute MI and impaired left ventricular systolic function, were randomly assigned 10 mg of dapagliflozin or placebo, given once daily. The primary outcome was the hierarchical composite of death, hospitalization for heart failure, nonfatal MI, atrial fibrillation/flutter, type 2 diabetes mellitus, New York Heart Association Functional Classification at the last visit, and body weight decrease of 5% or greater at the last visit using the win ratio analysis method. The key secondary outcome was the same hierarchical composite excluding the body weight component. RESULTS: We enrolled 4017 patients of whom 2019 were assigned to dapagliflozin and 1998 to placebo. The analysis of the primary hierarchical composite outcome resulted in significantly more wins for dapagliflozin than for placebo (win ratio, 1.34; 95% confidence interval [CI], 1.20 to 1.50; P<0.001). The win ratio outcome, which was adopted in a change of analysis during trial performance because of low event accrual, was mainly driven by the added cardiometabolic outcomes. The composite of time to cardiovascular death/hospitalization for heart failure occurred in 50/2019 (2.5%) patients assigned to dapagliflozin and 52/1998 (2.6%) patients assigned to placebo (hazard ratio, 0.95; 95% CI, 0.64 to 1.40). The rates of other cardiovascular events were low, with differences between the groups not reaching nominal statistical significance. No safety concerns were identified. CONCLUSIONS: In patients with acute MI as noted above, after approximately 1 year of treatment with dapagliflozin there were significant benefits with regard to improvement in cardiometabolic outcomes but no impact on the composite of cardiovascular death or hospitalization for heart failure compared with placebo. (Funded by AstraZeneca; ClinicalTrial.gov number, NCT04564742.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Self-citationJernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M., & Janzon, M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu505 · Cited by 875
Pocock, S. J., Ariti, C. A., Collier, T. J., & Wang, D. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr352 · Cited by 812
Jernberg, T., Attebring, M. F., Hambraeus, K., Ivert, T., James, S., Jeppsson, A., Lagerqvist, B., Lindahl, B., Stenestrand, U., & Wallentin, L. (2010) · Heart · doi:10.1136/hrt.2010.198804 · Cited by 773
Self-citationCOVID-19 pandemic and admission rates for and management of acute coronary syndromes in england
Mafham, M. M., Spata, E., Goldacre, R., Gair, D., Curnow, P., Bray, M., Hollings, S., Roebuck, C., Gale, C. P., Mamas, M. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31356-8 · Cited by 714
Self-citationCardiovascular disease in Europe — epidemiological update 2015
Townsend, N., Nichols, M., Scarborough, P., & Rayner, M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv428 · Cited by 568
Szummer, K., Wallentin, L., Lindhagen, L., Alfredsson, J., Erlinge, D., Held, C., James, S., Kellerth, T., Lindahl, B., Ravn-Fischer, A., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx515 · Cited by 443
Self-citationOxygen Therapy in Suspected Acute Myocardial Infarction
Hofmann, R., James, S. K., Jernberg, T., Lindahl, B., Erlinge, D., Witt, N., Arefalk, G., Frick, M., Alfredsson, J., Nilsson, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706222 · Cited by 384
Self-citationFurtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 329
Self-citationAngiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
Pfeffer, M. A., Claggett, B., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J.-L., Solomon, S. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104508 · Cited by 307
Empagliflozin in acute myocardial infarction: the EMMY trial
von Lewinski, D., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Benedikt, M., Wallner, M., Alber, H., Berger, R., Lichtenauer, M., Saely, C. H., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac494 · Cited by 303
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
Erlinge, D., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., Hamid, M., Swahn, E., Henareh, L., Wagner, H., Hårdhammar, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706443 · Cited by 301
Self-citationThe Myocardial Ischaemia National Audit Project (MINAP)
Herrett, E., Smeeth, L., Walker, L., Weston, C., & on behalf of the MINAP Academic Group (2010) · Heart · doi:10.1136/hrt.2009.192328 · Cited by 297
Jhund, P. S., Kondo, T., Butt, J. H., Docherty, K. F., Claggett, B. L., Desai, A. S., Vaduganathan, M., Gasparyan, S. B., Bengtsson, O., Lindholm, D., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01971-4 · Cited by 291
Self-citationThe win ratio approach for composite endpoints: practical guidance based on previous experience
Redfors, B., Gregson, J., Crowley, A., McAndrew, T., Ben-Yehuda, O., Stone, G. W., & Pocock, S. J. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa665 · Cited by 206
Szummer, K. E., Wallentin, L. C., Lindhagen, L., Alfredsson, J., Erlinge, D., Held, C., James, S. K., Kellerth, T., Lindahl, B., Ravn‐Fischer, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy554 · Cited by 153
Self-citationSandforth, A., von Schwartzenberg, R. J., Arreola, E. V., Hanson, R. L., Sancar, G., Katzenstein, S., Lange, K., Preißl, H., Dreher, S. I., Weigert, C., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00235-8 · Cited by 100
Rossing, P. R., Inzucchi, S. E., Vart, P., Jongs, N., Docherty, K. F., Jhund, P. S., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P. P., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00295-3 · Cited by 89
Self-citationDesta, L., Jernberg, T., Spaak, J., Hofman‐Bang, C., & Persson, H. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.086 · Cited by 47
Wu, J., Mamas, M. A., de Belder, M., Deanfield, J. E., & Gale, C. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.039 · Cited by 46
Self-citationOstrominski, J. W., Vaduganathan, M., Claggett, B. L., de Boer, R. A., Desai, A. S., Dobreanu, D., Hernandez, A. F., Inzucchi, S. E., Jhund, P. S., Kosiborod, M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2652 · Cited by 41
Self-citationJames, S. K., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Björkgren, I., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Rizi, E. P., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.08.008 · Cited by 40
Self-citation
Cited by
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Empagliflozin after Acute Myocardial Infarction
Butler, J., Jones, W. S., Udell, J. A., Anker, S. D., Petrie, M. C., Harrington, J., Mattheus, M., Zwiener, I., Amir, O., Bahit, M. C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2314051 · Cited by 301
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf301 · Cited by 9
Metadata
- Authors
- James, S., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Eriksson, N., Andersen, K., Austin, D., Arefalk, G., Carrick, D., Hofmann, R., Hoole, S. P., Jones, D. A., Lee, K., Tygesen, H., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Parvaresh Rizi, E., Deanfield, J., & Oldgren, J.
- Venue
- NEJM Evidence
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-23
- Volume
- 3
- Issue
- 2
- Pages
- EVIDoa2300286-EVIDoa2300286
- ISSN
- 2766-5526 (ISSN-L)
- OpenAlex
- W4388592138
- Cited by
- 305
- References
- 31
- FWCI
- 50.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.